Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
|Slideshows|July 2, 2019
The top 5 studies from June 2019
Ranging from biomarkers that can define PTB risk to the impact of age and fertility, these are five of the most noteworthy studies published in June 2019.
Advertisement
Advertisement
Related to this article
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.
The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
How estrogen-centered menopause care sidelined testosterone in women
2
Testosterone for women: Global consensus and physiologic dosing
3
What biomarker-guided preeclampsia care could look like
4
Testosterone physiology in women and the long road to approval
5